UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. This milestone indicates a new era for millions of women suffering from SUI, and signals an exciting transition for surgeons treating SUI not only in France, where the female patient was treated, but also across Europe and the U.S. It also follows closely on the heels of the successful results of the complete treatment cohort of the first-in-man clinical feasibility study. Results of this clinical study will contribute to the design and implementation of UroMems‘ pivotal clinical trial in Europe and the U.S.

Pharma- und Biotechnologieunternehmen, die sich in der Open Pharma Collaboration zusammengeschlossen haben, haben heute den dringenden Bedarf an leicht verständlichen Zusammenfassungen in medizinischen Fachzeitschriften mit Peer-Review bekannt gegeben.

CRISPR/Cas-Systeme haben im letzten Jahrzehnt enorme Fortschritte gemacht. Diese präzisen Genom-Editierwerkzeuge finden Anwendung in der Entwicklung transgener Pflanzen bis hin zur Gentherapie und darüber hinaus. Und mit ihrer jüngsten Entwicklung von CRISPR-COPIES verbessern die Forscher des Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) die Vielseitigkeit und Benutzerfreundlichkeit von CRISPR weiter.

Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies‘ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most common limitations of targeted methylation analysis and enabling WBL to create custom methylation panels that target an unprecedented hundreds-to-thousands of genomic loci of interest with an enrichment of 400-2300x Clinical applications have historically been hindered by available methods to analyze DNA methylation. Bisulfite sequencing, which involves chemical treatment of DNA with sodium bisulfite and PCR amplification, remains the de facto standard for DNA methylation analysis. However, bisulfite conversion is known to damage DNA, and amplification is prone to errors and biases. Because of these limitations, WBL has developed a targeted sequencing protocol that is bisulfite and PCR amplification free.… 

Researchers at Children’s Hospital Los Angeles report in The Journal of Molecular Diagnostics about a new tool that effectively integrates data from four fusion callers and identifies disease-related gene fusions Philadelphia, February 13, 2024 – Identification of specific gene fusions is critical for the successful targeted treatment of pediatric cancer patients. Researchers at Children’s Hospital Los Angeles have developed a novel assay that automatically integrates the data from multiple fusion identification tools (callers) and efficiently and accurately identifies clinically relevant gene fusions in pediatric tumors. Their results are reported in The Journal of Molecular Diagnostics, published by Elsevier. „An Exome Capture-Based RNA-Sequencing Assay for Genome-Wide Identification and Prioritization of Clinically Important Fusions in Pediatric Tumors,” by Jonathan Buckley, Ryan J. Schmidt, Dejerianne Ostrow, Dennis Maglinte, Moiz Bootwalla, David Ruble, Ananthanarayanan Govindarajan, Jianling Ji, Alexandra E. Kovach, Etan Orgel, Gordana Raca, Fariba Navid, Leo Mascarenhas, Bruce Pawel,…